LCTX

#3121
Lineage Cell Therapeutics, Inc.
1.6050 USD
-1.83%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
1.6000
1.6400
Range Annuel
1.4200
1.9850
Changement quotidien
-1.83%
Changement Mensuel
+0.31%
Evolution sur 6 mois
-6.52%
Changement Annuel
-6.52%
Clôture Précédente
1.6350
Open
1.6400
Bid
Ask
Low
1.6000
High
1.6400
Volume
38
Open full chart

Financials

Overview Relevé Statistics
Quarterly Annual
  • Market Capitalization 399.7855 M
  • Employee 77
  • Founded 1990
  • CEO N/A
  • Website www.lineagecell.com
  • Headquarter California, United States
  • FIGI BBG000G8RJY6
  • Industry Biotechnologies
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-5.96
Price to sales ratio
26.4

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

Nouvelles